首页 > 市场调查报告书 > 製药

生物製剂

抗体发现市场（第五版）：服务和平台-按提供的服务类型、抗体发现方法、产生的抗体类型和关键区域分布：行业趋势和全球预测，2023-2035

市场调查报告书

商品编码

1358246

抗体发现市场（第五版）：服务和平台-按提供的服务类型、抗体发现方法、产生的抗体类型和关键区域分布：行业趋势和全球预测，2023-2035

Antibody Discovery Market (5th Edition): Focus on Services & Platforms-Distribution by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Key Geographies: Industry Trends & Global Forecasts, 2023-2035

出版日期: 2023年09月23日 | 出版商:

Roots Analysis | 英文 552 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

几十年来，外包一直是製药业的策略发展，公司将各种任务外包给外部供应商，以提高候选人的创新和效率。合约研发和製造组织利用其专业知识缩短研发时间并确保遵守严格的法规。这些组织提供风险分担和转移，并提高对市场成长的适应性。由于快速进入市场的需求和不断上升的开发成本，人们对外包生物製药业务的兴趣日益浓厚。随着製药公司继续拥抱这一趋势，外包预计将继续改变行业格局，优化营运并促进治疗创新的进步。

抗体发现服务和抗体发现平台市场是由生物技术的最新进步、靶向治疗需求的增加、慢性病数量的增加、製药公司研发费用的增加以及外包抗体发现的上升趋势推动的。驱动因素。此外，从事该行业的学术机构和抗体发现公司之间不断加强的合作也有助于市场成长。有趣的是，最近，2023 年 5 月，Nona Biosciences 与 ModeX Therapeutics 签署了一项协议，将 Harbor Mice(R) 技术整合到后者的 MSTAR 平台中，并发现改进的治疗选择。

获得抗体发现平台许可使公司能够获得开发治疗性抗体的创新工具和方法。最近的趋势更重视学术机构、生技新创公司和成熟製药公司之间的合作和伙伴关係。参与该市场的各大公司正在为此类抗体发现平台的对外许可/内向许可做出各种努力。

预计 2023 年至 2035 年期间，全球抗体发现服务和平台市场规模将以 11.0% 的复合年增长率成长。目前，在整个抗体发现服务/平台市场中，命中生成领域占了最大的市场份额（40%）。命中生成步骤通常使用高通量筛选和计算方法来加速药物发现，通常占抗体发现过程中研发成本的很大一部分。鑑于其在抗体发现过程中的重要性，预计这一趋势在预测期内不会改变。此外，就抗体发现方法而言，杂交瘤方法在整个抗体发现服务平台市场中占据最大的市场份额（超过30%）。杂交瘤方法透过将产生抗体的 B 细胞与骨髓瘤细胞融合，可以创建能够连续产生抗体的永生化细胞系，从而可以为各种治疗和研究应用创建靶向抗体，已被证明是有用的。

目前，北美公司占了近40%的市占率。在对先进抗体发现平台日益增长的兴趣以及製药行业不断增长的外包需求的推动下，北美抗体发现服务和平台市场规模预计在 2023-2035 年预测期内将以 12% 的复合年增长率扩大。

本报告调查了全球抗体发现市场，并提供了市场概述，以及有关提供的服务类型、抗体发现方法、生产的抗体类型、治疗领域趋势、地区趋势和市场进入的信息.我们提供公司简介等。

INTRODUCTION

The global antibody discovery services and platforms market size is estimated to be worth over $1.6 billion in 2023 and is expected to grow at a compounded annual growth rate (CAGR) of 12.0% during the forecast period.

The usual drug development process, beginning from discovery to commercialization of a clinically validated product spans around 10-15 years and requires investments of over $2 billion. , However, despite the extensive efforts and investments, over 90% of the drug candidates fail in clinical trials. In order to streamline the drug development processes, reduce timelines, and mitigate financial risks associated with failed trials, pharmaceutical players are increasingly outsourcing various aspects of their discovery-stage operations to specialized contract research organizations (CROs). By leveraging the capabilities of such antibody CRO, companies engaged in the antibody discovery market can optimize internal resource utilization and cost saving. Such strategic collaborations allow antibody discovery companies to tap into a global network of scientific talent, which leads to the enhancement of the overall efficiency and success rate of bringing novel antibody-based therapeutics to the market.

Since the approval of the first monoclonal antibody-based therapy, Orthoclone OKT3®, in 1986 , such antibodies have evolved into a versatile class of biopharmaceuticals, undergoing significant advancements in engineering, diversification of formats, and innovative discovery methods. Currently, more than 160 monoclonal antibodies have been approved by the various regulatory agencies around the world to be used in humans for the treatment of various diseases, including cancer, chronic inflammatory diseases, infectious diseases and cardiovascular diseases. , Some of the recently approved monoclonal antibody therapies include (in reverse chronological order of their approval date) ELREXFIO™ (August 2023) , TALVEY™ (August 2023) , Rystiggo® (June 2023) , COLUMVI® (June 2023) and EPKINLY™ (May 2023) . Owing to the complexities associated with the discovery of such monoclonal antibodies, many firms are opting to license and utilize specialized antibody discovery platforms and technologies. Further, given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for antibody discovery services and platforms is likely to increase at a significant growth rate in the foreseen future.

SCOPE OF THE REPORT

The Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities within the antibody drug discovery services and platforms market during the forecast period. The market report highlights the efforts of the various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibody drug discovery services and platforms market are briefly discussed below.

Increasing Reliance on Outsourcing of Antibody Discovery to Contract Research Organizations

Outsourcing has been a strategic deployment of the pharmaceutical industry, for the past several decades, where companies delegate their various tasks to external vendors, in order to improve innovation and efficiency of their candidates. The contract research and manufacturing organizations accelerate the development timelines and ensure compliance with stringent regulations through their expertise. These organizations offer risk sharing and transfer and enhance adaptability to market growth. The growing interest in outsourcing of biopharmaceutical operations can be attributed to the need for rapid market access and the rising development costs. As pharmaceutical companies continue to embrace this trend, outsourcing is expected to continue to evolve the industry's landscape, optimizing operations and driving progress in therapeutic innovations.

Key Drivers of the Global Market for Antibody Discovery Services and Technologies

Recent advancements in biotechnology, increasing demand for targeted therapies, ever-increasing prevalence of chronic diseases, increase in R&D expenditure in pharma and growing trend for outsourcing antibody discovery are some of the key drivers of the antibody drug discovery services and antibody discovery platforms market growth. In addition, the increasing number of collaborations between academic institutions and antibody discovery companies engaged in this industry contributes to the market growth. It is interesting to note that recently, in May 2023, Nona Biosciences signed an agreement with ModeX Therapeutics in order to integrate Harbour Mice® technology into the latter's MSTAR platform for the discovery of improved treatment options.

Market Trends: Increase in Funding Activity in the Antibody Drug Discovery Service and Platform Domain

Owing to the increase in applications of antibody drug discovery services and platforms, the industry has garnered significant interest from investors, which has resulted in a strong spur in investment activity in this market. For instance, in January 2023, IASO Biotherapeutics USD 75 million in a venture series C round. Further, it is worth highlighting that, in the past two years, four antibody discovery companies (Apexigen, Biocytogen, Shandong Boan Biotechnology and Twist Bioscience) have collectively raised over USD 375 million through initial public offerings. The funds raised by the companies operating in antibody discovery market will continue to advance the development of next generation antibody discovery platforms, which will support the development of novel antibody-based therapeutics driving the market growth over the forecast period.

Furthermore, several companies are entering into mergers and acquisitions to expand the service offerings in the antibody discovery market. In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary. The company acquired Abveris, an antibody discovery CRO in 2022 to gain hold of its single cell screening and hybridoma approach.

Recent Trends on the Licensing of Antibody Discovery Platforms

Licensing of antibody discovery platforms enables the companies to access innovative tools and methods for developing therapeutic antibodies, allowing firms to leverage specialized expertise and expand their R&D capabilities by avoiding the spend on the technology. Recent trends highlight a growing emphasis on collaborations and partnerships between academic institutes, biotechnology startups, and established pharmaceutical companies. Various key players engaged in this market have undertaken various initiatives to out-license / in-license several such antibody discovery platforms. For instance, recently, in June 2023, AbTherx entered into an agreement with Gilead Sciences in order to in-license latter's novel transgenic mouse technology, named Atlas™ Mice. In addition, in January 2023, Hummingbird Bioscience entered into an agreement with Synaffix in order to utilize Synaffix's proprietary technologies, GlycoConnect™ and HydraSpace™.

Market Size: Key Segments of the Antibody Drug Discovery Services and Platforms Market

At present, the hit generation segment captures the largest market share (40%) of the overall antibody discovery services and platforms market. The hit generation step, which usually employs high-throughput screening and computational methods to accelerate drug discovery, generally accounts for the major proportion of the R&D expenditure in the antibody discovery processes. Given its significance in antibody discovery processes, this trend is unlikely to change during the forecast period. Further, in terms of the antibody discovery method, hybridoma method captures the largest market share (over 30%) of the overall antibody discovery services and platforms market. Owing the capability of hybridoma method to lead the fusion of antibody-producing B cells with myeloma cells in order to create immortalized cell lines capable of continuous antibody production, this method has proven valuable for generating targeted antibodies for various therapeutic and research applications.

Regional Analysis: North America Holds the Largest Market Share of Antibody Drug Discovery Services and Platforms Market

Presently, close to 40% of the market is captured by companies based in North America. Driven by the rising interest in advanced antibody discovery platforms and increasing need for outsourcing in the pharmaceutical industry, the market size for antibody drug discovery services and platforms in North America is anticipated to grow at a CAGR of 12%, during the forecast period, 2023-2035. Several factors contribute to the region's dominance in this domain, which include the presence of big pharma companies with well-established R&D divisions that foster innovation and drive the demand for advanced antibody discovery platforms.

Key Players Engaged in Antibody Discovery Services and Platforms Market

Examples of key players (which have also been profiled in this market report) engaged in antibody discovery market include (in alphabetical order) Ablexis, Antibody Solutions, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, Myrio Therapeutics, Nona Biosciences, Rockland Immunochemicals, Synbio technologies and WuXi Biologics. This market report includes an easily searchable excel database of all the antibody discovery service providers and antibody discovery platform providers worldwide.

Recent Developments in Antibody Discovery Services and Platforms Market

Several recent developments have taken place in the field of antibody discovery in terms of both services and platforms. We've outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we've outlined in our analysis.

In June 2023, AbTherx announced the launch of its transgenic mouse-based antibody discovery platform, Atlas™ Mice.
In June 2023, another China based company Sanyou Biopharmaceuticals launched its Sanyou Super Trillion Common Light Chain Antibody Discovery Platform, which supports the discovery of bispecific antibody formats.

The market research report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies. Amongst other elements, the market report features:

A preface providing an introduction to the full report, Antibody Discovery Services and Platforms Market (5th Edition), 2017-2022 (Historical Trends) and 2023-2035 (Forecasted Estimates).
An outline of the systematic research methodology adopted to conduct the study on antibody discovery services and platforms market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall antibody discovery services and platforms market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the key insights captured in our research. It offers a high-level view on the current state of the antibody discovery services and platforms market and its likely evolution in the short to mid and long term.
A general introduction of antibodies, featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.
A detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also features a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.
A general overview of the current market landscape of over 160 service providers that are currently active in the antibody discovery services market. It features a detailed analysis of these service providers based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
An insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies based on their years of experience, number of platforms, number of antibody discovery services offered, types of antibody discovery methods adopted, type of antibody formats generated, type of application areas. The chapter also presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered by the platform providers.
Detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, recent developments and an informed future outlook.
An overview of the current market landscape of over 290 antibody discovery platforms, including in-depth analyses on type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others), type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others) and animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others). In addition, the chapter highlights insightful analyses of 190+ antibody discovery platform providers based on their company details such as year of establishment, company size and location of headquarters.
An insightful competitiveness analysis of antibody discovery technologies, highlighting the leading players in this market, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human, number of deals signed for a particular platform (2015-2023).
Detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery platform / technology to other companies. Each company profile includes a brief overview of the company, details on antibody discovery platforms / technology, recent developments and an informed future outlook.
An in-depth analysis and discussion on the various partnerships that have been inked between the players in antibody discovery services and platforms market in the time period between 2021 and 2023. It includes a brief description of partnership models (such as acquisitions, clinical trial agreements, mergers, multipurpose agreements, product / technology licensing agreements, product development and commercialization agreements, research and development agreements, service agreements, technology integration agreements, technology utilization agreements) adopted by the stakeholders.
An analysis of the funding and investments made in antibody discovery services and platforms market during the period 2016-2023, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of antibody discovery.
An insightful deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.
A SWOT analysis on antibody humanization services, highlighting industry-specific trends, key market drivers and challenges for players engaged in providing such services. In addition, the chapter presents a list of key players that perform antibody humanization and affinity maturation services along with information on their respective location and the methodology adopted by such players. Further, this chapter elaborates on the factors that are likely to influence the activities of companies engaged in offering such services.
Detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2022). It provides detailed profiles on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Darzalex®, including information on their historical sales, discovery process and methods.
An overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry's evolution over the coming decade.

One of the key objectives of the market report was to estimate the current opportunity and future growth potential for antibody discovery services and platforms market over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), type of antibody generated (monoclonal antibodies, bispecific antibodies and others), nature of antibody generated (chimeric, human, humanized and murine), type of therapeutic areas (cardiovascular disorders, immunological disorders, infectious disorders, neurological disorders, oncological disorders and others) and key geographical regions (North America, Europe and Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

John S Kenney (Founder and President, Antibody Solutions)
Guy Van Meter (Chief Business Officer, Adimab)
Kari Graber (Vice President of Commercial Services)
Anonymous (Chief Business Officer, US based Mid-sized Company)
Tracey Mullen (Former Chief Executive Officer, Abveris Antibody (acquired by Twist Bioscience))
Lisa Delouise (Founder and Chief Technology Officer, Nidus BioSciences)
Mark Kubik (Former Chief Business Officer, AvantGen)
Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
Giles Day (Co-founder and Former Chief Executive Officer, Distributed Bio)
Kevin Heyries (Co-founder and Former Lead of Business Development Strategy, AbCellera)
Sanjiban K Banerjee (Co-founder and Director, AbGenics Life Sciences)
Ignacio Pino (Co-founder and Chief Operating Officer, CDI Laboratories)
Jeng Her (Chief Executive Officer, AP Biosciences)
Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
Debra Valsamis (Business Development Associate, Antibody Solutions)
Christel Iffland (Senior Vice President, Ligand Pharmaceuticals)
Aaron Sato (Former Chief Scientific Officer, LakePharma)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this market report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What are antibody discovery services?

Answers: Antibody discovery services are service offerings of the pharmaceutical contract research organizations to assist in the identification of the antibody drug targets and development of antibodies.

Question 2: What are the methods of antibody discovery?

Answers: Antibody discovery utilizes various techniques, such as phage display, hybridoma technology, and next generation sequencing, to generate antibodies that can target specific antigens.

Question 3: What is the importance of antibody drug discovery services and platforms in the healthcare sector?

Answer: Antibody drug discovery services and platforms are vital in expediting the development of antibodies. Such offerings provide pharmaceutical companies with specialized expertise, advanced technologies, and cost efficiencies. Further, it helps to accelerate drug development and allows faster commercialization of a drug candidate.

Question 4: What is the likely market size of the antibody discovery services and platforms market?

Answers: The global antibody discovery services and platforms market is expected to be worth USD 32.1 billion by 2035.

Question 5: What is the estimated growth rate (CAGR) of the antibody discovery services and platforms market?

Answers: The global antibody discovery services and platforms market size is anticipated to grow at a compound annual growth rate (CAGR) of 11.0%, during the forecast period 2023-2035.

Question 6: Which region is likely to hold the largest market share in the global antibody discovery services and platforms market?

Answers: Currently, North America and Europe collectively hold 65% of the market share. However, in the long run, the market in Asia is expected to grow at a relatively faster pace.

Question 7: What is the trend of capital investments in the antibody discovery services and platforms market?

Answers: Owing to the lucrative market opportunity associated with antibody discovery services and platforms, several investors have collectively invested nearly USD 24 billion, during the period 2016-2023.

Question 8: Which antibody discovery step currently accounts for the largest market share in the antibody discovery services and platforms market?

Answers: At present, the hit generation segment captures the largest market share (40%) of the overall antibody discovery services and platforms market. This trend is unlikely to change during the forecast period.

Question 9: Which are the leading market segments in antibody discovery services and platforms market, in terms of antibody discovery method?

Answers: At present, the hybridoma segment captures the largest market share (over 30%) of the overall antibody discovery services and platforms market.

Question 10: What are the key factors contributing to the growth of antibody discovery services and platforms market?

Answers: The antibody discovery services and platforms market is likely to be driven by increasing demand for therapeutic antibodies, advancements in screening and computational methods, customization for personalized treatments, increasing number of strategic collaborations, emerging disease targets, and integration of data science and AI for improved efficiency.

CHAPTER OUTLINES

Chapter 1 is a preface providing an introduction to the full report, Antibody Discovery Services and Platforms Market (5th Edition), 2017-2022 (Historical Trends) and 2023-2035 (Future Estimates).

Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on antibody discovery services and platforms market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of findings.

Chapter 3 provides an overview of economic factors that impact the overall antibody discovery services and platforms market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.

Chapter 4 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the antibody drug discovery services and platforms market and its likely evolution in the short to mid and long term.

Chapter 5 provides a general introduction of antibodies, featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.

Chapter 6 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also features a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 7 provides a general overview of the antibody discovery services market landscape of over 160 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).

Chapter 8 provides an insightful competitiveness analysis of antibody discovery service providers captured during our research. The analysis compares the companies based on years of experience, number of platforms, number of antibody discovery services offered, types of antibody discovery methods adopted, type of antibody formats generated, type of application areas. The chapter also presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.

Chapter 9 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, recent developments and an informed future outlook.

Chapter 10 presents the current market landscape of over 290 antibody discovery platforms, including in-depth analyses on type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others), type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others) and animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others). In addition, the chapter highlights insightful analyses of 190+ antibody discovery platform providers based on their company details such as year of establishment, company size and location of headquarters.

Chapter 11 provides an insightful competitiveness analysis of antibody discovery technologies. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human (humanized or fully human), number of deals signed for a particular platform (2015-2023).

Chapter 12 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery platform / technology to other companies. Each company profile includes a brief overview of the company, details on antibody discovery technology / platforms, recent developments and an informed future outlook.

Chapter 13 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in antibody discovery services and platform market in the time period between 2021 and 2023. It includes a brief description of partnership models (such as acquisitions, clinical trial agreements, mergers, multipurpose agreements, product / technology licensing agreements, product development and commercialization agreements, research and development agreements, service agreements, technology integration agreements, technology utilization agreements) adopted by the stakeholders.

Chapter 14 presents an analysis of the funding and investments made in antibody discovery services and platforms market during the period 2016-2023, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.

Chapter 15 features an in-depth analysis of the factors that can impact the growth of antibody discovery services and platforms market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges

Chapter 16 features a detailed market forecast analysis in order to estimate the existing market size and future opportunity for antibody discovery services over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the antibody discovery services market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 17 provides detailed projections of the current and future antibody discovery services market across different steps involved in antibody discovery, such as antigen designing, hit generation, lead selection, lead optimization and lead characterization.

Chapter 18 provides detailed projections of the current and future antibody discovery services market across different antibody discovery methods, such as hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others.

Chapter 19 provides detailed projections of the current and future antibody discovery services market across the nature of antibody generated, such as chimeric, human, humanized and murine antibodies.

Chapter 20 provides detailed projections of the current and future antibody discovery services market across the type of therapeutic areas, such as oncological disorders, immunological disorders, infectious disorders, neurological disorders, cardiovascular disorders and others.

Chapter 21 provides detailed projections of the current and future antibody discovery services market across the key geographical regions, such as North America, Europe and Asia, Latin America, Middle East and North Africa, and rest of the world.

Chapter 22 presents a detailed market forecast analysis in order to estimate the existing market size and future opportunity for antibody discovery platforms over the next decade. Based on multiple parameters, licensing deal trends, and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the antibody discovery technologies market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 23 provides detailed projections of the current and future antibody discovery technologies market across the type of antibody generated, such as monoclonal antibodies, bispecific antibodies and others.

Chapter 24 provides detailed projections of the current and future antibody discovery technologies market across the key geographical regions, such as North America, Europe and Asia, Latin America, Middle East and North Africa, and rest of the world.

Chapter 25 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

Chapter 26 features a SWOT analysis on antibody humanization services, highlighting industry-specific trends, key market drivers and challenges for players engaged in providing such services. In addition, the chapter presents a list of key players that perform antibody humanization and affinity maturation services along with information on their respective location and the methodology adopted by such players. Further, this chapter elaborates on the factors that are likely to influence the activities of companies engaged in offering such services.

Chapter 27 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2022). It provides detailed profiles on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Darzalex®, their historical sales, and discovery process and methods.

Chapter 28 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry's evolution over the coming decade.

Chapter 29 summarizes the entire report, highlighting the various facts related to contemporary market trends and the likely evolution of the antibody discovery service and platform market.

Chapter 30 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (arranged in reverse chronological order of the date when the interview was conducted), John S Kenney (Founder and President, Antibody Solutions) Q3 2023, Guy Van Meter (Chief Business Officer, Adimab) Q3 2023, Kari Graber (Vice President of Commercial Services) Q3 2023, Anonymous (Chief Business Officer, US based Mid-sized Company) Q3 2023, Tracey Mullen (Former Chief Executive Officer, Abveris Antibody, acquired by Twist Bioscience) Q2 2020, Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences) Q1 2020, Mark Kubik (Former Chief Business Officer, AvantGen) Q1 2020, Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology) Q2 2018, Giles Day (Co-founder and Chief Executive Officer, Distributed Bio) Q2 2018, Kevin Heyries (Co-founder and Former Lead of Business Development Strategy, AbCellera) Q2 2018, Sanjiban K Banerjee (Co-founder and Director, AbGenics Life Sciences) Q2 2018, Ignacio Pino (Co-founder and Chief Operating Officer, CDI Laboratories) Q2 2017, Jeng Her (Chief Executive Officer, AP Biosciences) Q2 2017, Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB) Q2 2017, Debra Valsamis (Business Development Associate, Antibody Solutions) Q2 2017, Christel Iffland (Senior Vice President, Ligand Pharmaceuticals) Q2 2017, Aaron Sato (Former Chief Scientific Officer, LakePharma) Q2 2017.

Chapter 31 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 32 is an appendix, which contains the list of companies and organizations mentioned in the report.

1. PREFACE

1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
- 5.6.1. Monoclonal Antibodies
- 5.6.2. Polyclonal Antibodies
- 5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies
5.8. Concluding Remarks

6. ANTIBODY DISCOVERY: PROCESS AND METHODS

6.1. Chapter Overview
6.2. Antibody Discovery Process
- 6.2.1. Target Selection and Validation
- 6.2.2. Hit Generation
- 6.2.3. Lead Selection
- 6.2.4. Lead Optimization
  - 6.2.4.1. Humanization
  - 6.2.4.2. Affinity Maturation
  - 6.2.4.3. Fc Engineering
- 6.2.5. Lead Characterization
- 6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
- 6.3.1. Hybridoma Technology-based Method
- 6.3.2. In vitro Display Method
  - 6.3.2.1. Phage Display
  - 6.3.2.2. Yeast Display
  - 6.3.2.3. Ribosomal Display
- 6.3.3. Transgenic Animal-based Method
- 6.3.4. Single B Cell-based Method
- 6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
6.4. Evolution of Monoclonal Antibodies
- 6.4.1. Fully Human Monoclonal Antibodies
6.5. Concluding Remarks

7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters
- 7.2.4. Analysis by Type of Service Offered
- 7.2.5. Analysis by Type of Antibody Discovered
- 7.2.6. Analysis by Type of Antibody Discovery Method
- 7.2.7. Analysis by Animal Model Used
- 7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
- 7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
- 7.2.10. Analysis by Application Area

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped based on Company Size
- 8.4.1. Very Small Companies Offering Antibody Discovery Services
- 8.4.2. Small Companies Offering Antibody Discovery Services
- 8.4.3. Mid-sized Companies Offering Antibody Discovery Services
- 8.4.4. Large Companies Offering Antibody Discovery Services
8.5. Antibody Discovery Service Providers: Regional Capability
- 8.5.1. Antibody Discovery Service Providers based in North America
- 8.5.2. Antibody Discovery Service Providers based in Europe
- 8.5.3. Antibody Discovery Service Providers based in Asia

9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
- 9.2.1. Abwiz Bio
  - 9.2.1.1. Company Overview
  - 9.2.1.2. Recent Developments and Future Outlook

9.2.2. Aragen Bioscience (Subsidiary of GVK BIO)
- 9.2.2.1. Company Overview
- 9.2.2.2. Recent Developments and Future Outlook
9.2.3. Creative Biolabs
- 9.2.3.1. Company Overview
- 9.2.3.2. Recent Developments and Future Outlook
9.2.4. Distributed Bio
- 9.2.4.1. Company Overview
- 9.2.4.2. Recent Developments and Future Outlook
9.2.5. ImmunoPrecise Antibodies
- 9.2.5.1. Company Overview
- 9.2.5.2. Financial Information
- 9.2.5.3. Recent Developments and Future Outlook

9.2.6. Integral Molecular
- 9.2.6.1. Company Overview
- 9.2.6.2. Recent Developments and Future Outlook
9.2.7. LakePharma
- 9.2.7.1. Company Overview
- 9.2.7.2. Recent Developments and Future Outlook
9.2.8. Syd Labs
- 9.2.8.1. Company Overview
- 9.2.8.2. Recent Developments and Future Outlook

9.3. Antibody Discovery Service Providers in Europe
- 9.3.1. Abzena
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Financial Information
  - 9.3.1.3. Recent Developments and Future Outlook
- 9.3.2. BIOTEM
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Recent Developments and Future Outlook
- 9.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Recent Developments and Future Outlook
9.4. Antibody Discovery Service Providers in Asia and Rest of the World
- 9.4.1. ChemPartner
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Recent Developments and Future Outlook
- 9.4.2. HD Biosciences
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Recent Developments and Future Outlook
- 9.4.3. Viva Biotech
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Financial Information
  - 9.4.3.3. Recent Developments and Future Outlook
- 9.4.4. WuXi Biologics
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Financial Information
  - 9.4.4.3. Recent Developments and Future Outlook

10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE

10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies and Platforms
- 10.2.1. Analysis by Type of Antibody Discovery Method
- 10.2.2. Analysis by Type of Antibody Discovered
- 10.2.3. Analysis by Animal Model Used
- 10.2.4. Analysis by Type of Antibody Discovery Method and Location of Headquarters
- 10.2.5. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.3. Antibody Discovery Technologies: List of Industry Players
- 10.3.1. Analysis by Year of Establishment
- 10.3.2. Analysis by Company Size
- 10.3.3. Analysis by Location of Headquarters
- 10.3.4. Most Active Players: Analysis by Number of Platforms

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
- 11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
- 11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
- 11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World

12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

12.1. Chapter Overview
12.2. Harbour BioMed
- 12.2.1. Company Overview
- 12.2.2. Antibody Discovery Platforms Portfolio
- 12.2.3. Recent Developments and Future Outlook
12.3. ImmunoPrecise Antibodies
- 12.3.1. Company Overview
- 12.3.2. Financial Information
- 12.3.3. Antibody Discovery Platforms Portfolio
- 12.3.4. Recent Developments and Future Outlook
12.4. Kymab
- 12.4.1. Company Overview
- 12.4.2. Antibody Discovery Platforms Portfolio
- 12.4.3. Recent Developments and Future Outlook
12.5. Ligand Pharmaceuticals
- 12.5.1. Company Overview
- 12.5.2. Financial Information
- 12.5.3. Antibody Discovery Platforms Portfolio
- 12.5.4. Recent Developments and Future Outlook
12.6. MorphoSys
- 12.6.1. Company Overview
- 12.6.2. Financial Information
- 12.6.3. Antibody Discovery Platforms Portfolio
- 12.6.4. Recent Developments and Future Outlook

13. PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
- 13.3.1. Analysis by Year of Partnership
- 13.3.2. Analysis by Type of Partnership
- 13.3.3. Analysis by Year of Partnership and Type of Partner
- 13.3.4. Analysis by Type of Antibody
- 13.3.5. Most Active Players: Analysis by Number of Partnerships
- 13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
- 13.3.7. Analysis by Geography
- 13.3.8. Intracontinental and Intercontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS

14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
- 14.3.1. Analysis by Year of Funding
- 14.3.2. Analysis by Type of Funding
- 14.3.3. Analysis of Amount Invested by Year of Funding
- 14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
- 14.3.5. Most Active Players: Analysis by Number of Funding Instances
- 14.3.6. Most Active Players: Analysis by Amount Invested
- 14.3.7. Leading Investors: Analysis by Number of Funding Instances
- 14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
- 14.3.9. Analysis by Year-wise Amount Invested and Type of Player
- 14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
- 14.3.11. Analysis by Geography
14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET

16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 16.3.1. Scenario Analysis
16.4. Key Market Segmentations

16..5. Dynamic Dashboard

17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation

18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation

19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation

20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation

21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation

22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET

22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 22.3.1. Scenario Analysis
22.4. Key Market Segmentations
22.5. Dynamic Dashboard

23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation

24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation

25. LICENSING DEAL STRUCTURE

25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
- 25.3.1. Overall Cash Flow for Licensee Companies
  - 25.3.1.1. Investments Made by a Licensee
  - 25.3.1.2. Revenues Earned by a Licensee
- 25.3.2. Overall Cash Flow for Licensor Companies
  - 25.3.2.1. Investments Made by a Licensor
  - 25.3.2.2. Revenues Earned by a Licensor
25.4. Key Analytical Outputs
- 25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
- 25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
- 25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties

26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS

26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
- 26.3.1. Strengths
- 26.3.2. Weaknesses
- 26.3.3. Opportunities
- 26.3.4. Threats

27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

27.1. Chapter Overview
27.2. Humira® (Adalimumab)
- 27.2.1. Drug Overview
- 27.2.2. Discovery Process and Method
- 27.2.3. Historical Sales
27.3. Keytruda® (Pembrolizumab)
- 27.3.1. Drug Overview
- 27.3.2. Discovery Process and Method
- 27.3.3. Historical Sales
27.4. Stelara® (Ustekinumab)
- 27.4.1. Drug Overview
- 27.4.2. Discovery Process and Method
- 27.4.3. Historical Sales
27.5. Opdivo® (Nivolumab)
- 27.5.1. Drug Overview
- 27.5.2. Discovery Process and Method
- 27.5.3. Historical Sales
27.6. Darzalex® (Daratumumab)
- 27.6.1. Drug Overview
- 27.6.2. Discovery Process and Method
- 27.6.3. Historical Sales

28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks

29. CONCLUSION

30. EXECUTIVE INSIGHTS

30.1. Chapter Overview
30.2. Antibody Solutions
- 30.2.1. Company Snapshot
- 30.2.2. John S Kenney, Founder and President (Q3 2023)
30.3. Adimab
- 30.3.1. Company Snapshot
- 30.3.3. Guy Van Meter, Chief Business Officer (Q3 2023)
30.4. ImmunoPrecise Antibodies
- 30.4.1. Company Snapshot
- 30.4.3. Kari Graber, Vice President of Commercial Services (Q3 2023)
30.5. Anonymous
- 30.5.1. Anonymous, Chief Business Officer (Q3 2023)
30.6. Abveris, Acquired by Twist Biosciences
- 30.6.1. Company Snapshot
- 30.6.2. Tracey Mullen, Former Chief Executive Officer (Q2 2020)
30.7. Nidus BioSciences
- 30.7.1. Company Snapshot
- 30.7.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
30.8. AvantGen
- 30.8.1. Company Snapshot
- 30.8.2. Mark Kubik, Former Chief Business Officer (Q1 2020)
30.9. Single Cell Technology
- 30.9.1. Company Snapshot
- 30.9.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
30.10. Distributed Bio
- 30.10.1. Company Snapshot
- 30.10.2. Giles Day, Co-Founder and Former Chief Executive Officer (Q2 2018)
30.11. AbCellera
- 30.11.1. Company Snapshot
- 30.11.2. Kevin Heyries, Co-Founder and Former Lead of Business Development Strategy (Q2 2018)
30.12. AbGenics Life Sciences
- 30.12.1. Company Snapshot
- 30.12.2. Sanjiban K Banerjee, Co-founder and Director (Q2 2018)
30.13. CDI Laboratories
- 30.13.1. Company Snapshot
- 30.13.2. Ignacio Pino, Co-founder and Chief Executive Officer (Q2 2017)
30.14. AP Biosciences
- 30.14.1. Company Snapshot
- 30.14.2. Jeng Her, Chief Executive Officer (Q2 2017)
30.15. YUMAB
- 30.15.1. Company Snapshot
- 30.15.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
30.16. Antibody Solutions
- 30.16.1. Company Snapshot
- 30.16.2. Debra Valsamis, Business Development Associate (Q2 2017)
30.17. Ligand Pharmaceuticals
- 30.17.1. Company Snapshot
- 30.17.2. Christel Iffland, Senior Vice President (Q2 2017)
30.18. LakePharma
- 30.18.1. Company Snapshot
- 30.18.2. Aaron Sato, Former Chief Scientific Officer (Q2 2017)

31. APPENDIX 1: TABULATED DATA

32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

简介目录图表

List of Tables

Table 5.1 Antibody Isotypes: Key Features
Table 5.2 Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 5.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 7.1 Antibody Discovery Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 7.2 Antibody Discovery Service Providers: Information on Type of Services Offered
Table 7.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovered
Table 7.4 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method
Table 7.5 Antibody Discovery Service Providers: Information on Animal Model Used
Table 7.6 Antibody Discovery Service Providers: Information on Application Area
Table 8.1 Regional Capability Analysis: Antibody Discovery Service Providers Based in North America
Table 8.2 Regional Capability Analysis: Antibody Discovery Service Providers Based in Europe
Table 8.3 Regional Capability Analysis: Antibody Discovery Service Providers Based in Asia
Table 9.1 List of Companies Profiled
Table 9.2 Abwiz Bio: Company Snapshot
Table 9.3 Abwiz Bio: Recent Developments and Future Outlook
Table 9.4 Aragen Bioscience: Company Snapshot
Table 9.5 Aragen Bioscience: Recent Developments and Future Outlook
Table 9.6 Creative Biolabs: Company Snapshot
Table 9.7 Creative Biolabs: Recent Developments and Future Outlook
Table 9.8 Distributed Bio: Company Snapshot
Table 9.9 Distributed Bio: Recent Developments and Future Outlook
Table 9.10 ImmunoPrecise Antibodies: Company Snapshot
Table 9.11 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 9.12 Integral Molecular: Company Snapshot
Table 9.13 Integral Molecular: Recent Developments and Future Outlook
Table 9.14 LakePharma: Company Snapshot
Table 9.15 LakePharma: Recent Developments and Future Outlook
Table 9.16 Abzena: Company Snapshot
Table 9.17 Abzena: Recent Developments and Future Outlook
Table 9.18 BIOTEM: Company Snapshot
Table 9.19 BIOTEM: Recent Developments and Future Outlook
Table 9.20 PX'Therapeutics: Company Snapshot
Table 9.21 PX'Therapeutics: Recent Developments and Future Outlook
Table 9.22 ChemPartner: Company Snapshot
Table 9.23 ChemPartner: Recent Developments and Future Outlook
Table 9.24 Viva Biotech: Company Snapshot
Table 9.25 Viva Biotech: Recent Developments and Future Outlook
Table 9.26 WuXi Biologics: Company Snapshot
Table 9.27 WuXi Biologics: Recent Developments and Future Outlook
Table 10.1 Antibody Discovery Technologies: Information on Type of Antibody Discovered
Table 10.2 Antibody Discovery Service Technologies: Information on Type of Antibody Discovery Method
Table 10.3 Antibody Discovery Service Technologies: Information on Animal Model Used
Table 10.4 Antibody Discovery Service Technologies: Information on Location of Headquarters of Developer
Table 10.5 Antibody Discovery Platform Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 12.1 List of Companies Profiled
Table 12.2 Ablexis: Company Snapshot
Table 12.3 Ablexis: Antibody Discovery Platform Portfolio
Table 12.4 Ablexis: Recent Developments and Future Outlook
Table 12.5 Creative Biolabs: Company Snapshot
Table 12.6 Creative Biolabs: Antibody Discovery Platform Portfolio
Table 12.7 Creative Biolabs: Recent Developments and Future Outlook
Table 12.8 Genmab: Company Snapshot
Table 12.9 Genmab: Antibody Discovery Platform Portfolio
Table 12.10 Genmab: Recent Developments and Future Outlook
Table 12.11 Harbour BioMed: Company Snapshot
Table 12.12 Harbour BioMed: Antibody Discovery Platform Portfolio
Table 12.13 Harbour BioMed: Recent Developments and Future Outlook
Table 12.14 Immunome: Company Snapshot
Table 12.15 Immunome: Antibody Discovery Platform Portfolio
Table 12.16 Immunome: Recent Developments and Future Outlook
Table 12.17 Isogenica: Company Snapshot
Table 12.18 Isogenica: Antibody Discovery Platform Portfolio
Table 12.19 Isogenica: Recent Developments and Future Outlook
Table 12.20 Kymab: Company Snapshot
Table 12.21 Kymab: Antibody Discovery Platform Portfolio
Table 12.22 Kymab: Recent Developments and Future Outlook
Table 12.23 Ligand Pharmaceuticals: Company Snapshot
Table 12.24 Ligand Pharmaceuticals: Antibody Discovery Platform Portfolio
Table 12.25 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 12.26 MorphoSys: Company Snapshot
Table 12.27 MorphoSys: Antibody Discovery Platform Portfolio
Table 12.28 MorphoSys: Recent Developments and Future Outlook
Table 13.1 Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2023
Table 14.1 Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2023
Table 24.1 Developmental / Regulatory Milestones
Table 24.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 25.1 Approved Monoclonal Antibodies: Information on Affinity
Table 25.2 Antibody Humanization: List of Service Providers
Table 26.1 List of Top Ten Selling Therapeutic Antibodies, 2022
Table 29.1 Antibody Solutions: Company Snapshot
Table 29.2 Adimab: Company Snapshot
Table 29.3 ImmunoPrecise Antibodies: Company Snapshot
Table 29.4 Abveris Antibody: Company Snapshot
Table 29.5 Nidus BioSciences: Company Snapshot
Table 29.6 AvantGen: Company Snapshot
Table 29.7 Single Cell Technology: Company Snapshot
Table 29.8 Distributed Bio: Company Snapshot
Table 29.9 AbCellera: Company Snapshot
Table 29.10 AbGenics Life Sciences: Company Snapshot
Table 29.11 CDI Laboratories: Company Snapshot
Table 29.12 AP Biosciences: Company Snapshot
Table 29.13 YUMAB: Company Snapshot
Table 29.14 Antibody Solutions: Company Snapshot
Table 29.15 Ligand Pharmaceuticals: Company Snapshot
Table 29.16. LakePharma: Company Snapshot
Table 30.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 30.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 30.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 30.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 30.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 30.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 30.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 30.8 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Table 30.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Table 30.10 Antibody Discovery Service Providers: Analysis by Application Area
Table 30.11 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Table 30.12 Abzena: Annual Revenues, 2016-2022 (GBP Million)
Table 30.13 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Table 30.14 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Table 30.15 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Table 30.16 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Table 30.17 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Table 30.18 Antibody Discovery Technologies: Distribution by Animal Model Used
Table 30.19 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Table 30.20 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Table 30.21 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Table 30.22 Antibody Discovery Technology Providers: Distribution by Company Size
Table 30.23 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Table 30.24 Most Active Players: Distribution by Number of Technologies
Table 30.25 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Table 30.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 30.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Table 30.28 Partnerships and Collaborations: Distribution by Type of Antibody
Table 30.29 Most Active Players: Distribution by Number of Partnerships
Table 30.30 Most Popular Technologies: Distribution by Number of Partnerships
Table 30.31 Partnerships and Collaborations: Distribution by Geography
Table 30.32 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 30.33 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Table 30.34 Funding and Investment Analysis: Distribution by Type of Funding
Table 30.35 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Table 30.36 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Table 30.37 Most Active Players: Distribution by Number of Funding Instances
Table 30.38 Most Active Players: Distribution by Amount Invested (USD Million)
Table 30.39 Leading Investors: Distribution by Number of Funding Instances
Table 30.40 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Table 30.41 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Table 30.42 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Table 30.43 Funding and Investment Analysis: Distribution by Geography
Table 30.44 Global Antibody Discovery Services Market, Historical Trends, 2017-2022 (USD Million)
Table 30.45 Global Antibody Discovery Services Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 30.46 Antibody Discovery Services Market for Antigen Designing, Historical Trends 2017-2022 (USD Million)
Table 30.47 Antibody Discovery Services Market for Antigen Designing, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.48 Antibody Discovery Services Market for Hit Generation, Historical Trends, 2017-2022 (USD Million)
Table 30.49 Antibody Discovery Services Market for Hit Generation, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.50 Antibody Discovery Services Market for Lead Selection, Historical Trends, 2017-2022 (USD Million)
Table 30.51 Antibody Discovery Services Market for Lead Selection, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.52 Antibody Discovery Services Market for Lead Optimization, Historical Trends, 2017-2022 (USD Million)
Table 30.53 Antibody Discovery Services Market for Lead Optimization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.54 Antibody Discovery Services Market for Lead Characterization, Historical Trends, 2017-2022 (USD Million)
Table 30.55 Antibody Discovery Services Market for Lead Characterization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.56 Antibody Discovery Services Market for Phage Display, Historical Trends, 2017-2022 (USD Million)
Table 30.57 Antibody Discovery Services Market for Phage Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.58 Antibody Discovery Services Market for Yeast Display, Historical Trends, 2017-2022 (USD Million)
Table 30.59 Antibody Discovery Services Market for Yeast Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.60 Antibody Discovery Services Market for Hybridoma Method, Historical Trends, 2017-2022 (USD Million)
Table 30.61 Antibody Discovery Services Market for Hybridoma Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.62 Antibody Discovery Services Market for Transgenic Animal based Method, Historical Trends, 2017-2022 (USD Million)
Table 30.63 Antibody Discovery Services Market for Transgenic Animal based Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.64 Antibody Discovery Services Market for Single Cell based Method, Historical Trends, 2017-2022 (USD Million)
Table 30.65 Antibody Discovery Services Market for Single Cell based Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.66 Antibody Discovery Services Market for Other Antibody Discovery Method, Historical Trends, 2017-2022 (USD Million)
Table 30.67 Antibody Discovery Services Market for Other Antibody Discovery Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.68 Antibody Discovery Services Market for Humanized Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.69 Antibody Discovery Services Market for Humanized Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.70 Antibody Discovery Services Market for Human Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.71 Antibody Discovery Services Market for Human Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.72 Antibody Discovery Services Market for Chimeric Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.73 Antibody Discovery Services Market for Chimeric Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.74 Antibody Discovery Services Market for Murine Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.75 Antibody Discovery Services Market for Murine Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.76 Antibody Discovery Services Market for Oncological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.77 Antibody Discovery Services Market for Oncological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.78 Antibody Discovery Services Market for Immunological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.79 Antibody Discovery Services Market for Immunological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.80 Antibody Discovery Services Market for Infectious Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.81 Antibody Discovery Services Market for Infectious Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.82 Antibody Discovery Services Market for Neurological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.83 Antibody Discovery Services Market for Neurological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.84 Antibody Discovery Services Market for Cardiovascular Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.85 Antibody Discovery Services Market for Cardiovascular Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.86 Antibody Discovery Services Market for Other Disorders, Historical Trends, 2017-2022 (USD Million)
Table 30.87 Antibody Discovery Services Market for Other Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.88 Antibody Discovery Services Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 30.89 Antibody Discovery Services Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.90 Antibody Discovery Services Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 30.91 Antibody Discovery Services Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.92 Antibody Discovery Services Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 30.93 Antibody Discovery Services Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.94 Antibody Discovery Services Market in Latin America, Historical Trends, 2017-2022 (USD Million)
Table 30.95 Antibody Discovery Services Market in Latin America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.96 Antibody Discovery Services Market in Middle East and North Africa, Historical Trends, 2017-2022 (USD Million)
Table 30.97 Antibody Discovery Services Market in Middle East and North Africa, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.98 Antibody Discovery Services Market in Rest of the World, Historical Trends, 2017-2022 (USD Million)
Table 30.99 Antibody Discovery Services Market in Rest of the World, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.100 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022)
Table 30.101 Global Antibody Discovery Technologies Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.102 Antibody Discovery Technologies Market for Monoclonal Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.103 Antibody Discovery Technologies Market for Monoclonal Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.104 Antibody Discovery Technologies Market for Bispecific Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.105 Antibody Discovery Technologies Market for Bispecific Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.106 Antibody Discovery Technologies Market for Other Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 30.107 Antibody Discovery Technologies Market for Other Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.108 Antibody Discovery Technologies Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 30.109 Antibody Discovery Technologies Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.110 Antibody Discovery Technologies Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 30.111 Antibody Discovery Technologies Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.112 Antibody Discovery Technologies Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 30.113 Antibody Discovery Technologies Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 30.114 Humira®: Annual Sales, 2016-2022 (USD Billion)
Table 30.115 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Table 30.116 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Table 30.117 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Table 30.118 Darzalex®: Annual Sales, 2016-2022 (CHF Million)

List of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape of Antibody Discovery Service Providers
Figure 4.2 Executive Summary: Market Landscape of Antibody Discovery Platform Providers
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Market Sizing and Opportunity Analysis for Antibody Discovery Services
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis for Antibody Discovery Platforms
Figure 5.1 Basic Structure of an Antibody
Figure 5.2 Historical Timeline of Antibody Development
Figure 5.3 Mechanism of Action of Antibodies
Figure 5.4 Applications of Antibodies
Figure 6.1 Overview of the Antibody Discovery Process
Figure 6.2 Antibody Discovery Process: Hybridoma Method
Figure 6.3 Antibody Discovery Process: Phage Display Method
Figure 6.4 Antibody Generation Using Transgenic Animals
Figure 6.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 6.6 Approval Timeline of Fully Human Monoclonal Antibodies
Figure 6.7 Discovery Methods of Fully Human Monoclonal Antibodies
Figure 7.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 7.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 7.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 7.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 7.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 7.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 7.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 7.8 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Figure 7.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Figure 7.10 Antibody Discovery Service Providers: Analysis by Application Area
Figure 8.1 Competitiveness Analysis: Very Small Companies Offering Antibody Discovery Services
Figure 8.2 Competitiveness Analysis: Small Companies Offering Antibody Discovery Services
Figure 8.3 Competitiveness Analysis: Mid-sized Companies Offering Antibody Discovery Services
Figure 8.4 Competitiveness Analysis: Large Companies Offering Antibody Discovery Services
Figure 8.5 Regional Capability: Benchmarking of Players based in North America
Figure 8.6 Regional Capability: Benchmarking of Players based in Europe
Figure 8.7 Regional Capability: Benchmarking of Players based in Asia
Figure 9.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Figure 9.2 Abzena: Annual Revenues, 2016-2022 (GBP Million)
Figure 9.3 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Figure 9.4 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Figure 9.5 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Figure 10.1 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Figure 10.2 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Figure 10.3 Antibody Discovery Technologies: Distribution by Animal Model Used
Figure 10.4 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 10.5 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Figure 10.6 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Figure 10.7 Antibody Discovery Technology Providers: Distribution by Company Size
Figure 10.8 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Figure 10.9 Most Active Players: Distribution by Number of Technologies
Figure 11.1 Competitiveness Analysis: Technologies Offered by Companies based in North America
Figure 11.2 Competitiveness Analysis: Technologies Offered by Companies based in Europe
Figure 11.3 Competitiveness Analysis: Technologies Offered by Companies based in Asia and Rest of the World
Figure 13.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Antibody
Figure 13.5 Most Active Players: Distribution by Number of Partnerships
Figure 13.6 Most Popular Technologies: Distribution by Number of Partnerships
Figure 13.7 Partnerships and Collaborations: Distribution by Geography
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Figure 14.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 14.3 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Figure 14.4 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Figure 14.5 Most Active Players: Distribution by Number of Funding Instances
Figure 14.6 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.7 Leading Investors: Distribution by Number of Funding Instances
Figure 14.8 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Figure 14.9 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Figure 14.10 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Figure 14.11 Funding and Investment Analysis: Distribution by Geography
Figure 14.12 Funding and Investment Analysis: Concluding Remarks
Figure 15.1 Market Drivers
Figure 15.2 Market Restrainers
Figure 15.3 Market Opportunities
Figure 15.4 Market Challenges
Figure 16.1 Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.2 Global Antibody Discovery Services Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 16.3 Global Antibody Discovery Services Market, 2023-2035, Conservative Scenario (USD Million)
Figure 17.1 Antibody Discovery Services Market for Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.2 Antibody Discovery Services Market for Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.3 Antibody Discovery Services Market for Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.4 Antibody Discovery Services Market for Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.5 Antibody Discovery Services Market for Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.1 Antibody Discovery Services Market for Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.2 Antibody Discovery Services Market for Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.3 Antibody Discovery Services Market for Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.4 Antibody Discovery Services Market for Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.5 Antibody Discovery Services Market for Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.6 Antibody Discovery Services Market for Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.1 Antibody Discovery Services Market for Humanized Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.2 Antibody Discovery Services Market for Human Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.3 Antibody Discovery Services Market for Chimeric Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.4 Antibody Discovery Services Market for Murine Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.1 Antibody Discovery Services Market for Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.2 Antibody Discovery Services Market for Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.3 Antibody Discovery Services Market for Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.4 Antibody Discovery Services Market for Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.5 Antibody Discovery Services Market for Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.6 Antibody Discovery Services Market for Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.1 Antibody Discovery Services Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.2 Antibody Discovery Services Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.3 Antibody Discovery Services Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.4 Antibody Discovery Services Market in Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.5 Antibody Discovery Services Market in Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.6 Antibody Discovery Services Market in Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 22.1 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.2 Global Antibody Discovery Technologies Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 22.3 Global Antibody Discovery Technologies Market, 2023-2035, Conservative Scenario (USD Million)
Figure 23.1 Antibody Discovery Technologies Market for Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.2 Antibody Discovery Technologies Market for Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.3 Antibody Discovery Technologies Market for Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.1 Antibody Discovery Technologies Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.2 Antibody Discovery Technologies Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.3 Antibody Discovery Technologies Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 25.1 Licensing Agreements: Distribution of Financial Components
Figure 25.2 Technology Licensing Deal: Payment Structure
Figure 26.1 Antibody Humanization Services and Platforms: SWOT Analysis
Figure 26.2 Antibody Humanization Services and Platforms: Strengths
Figure 26.3 Antibody Humanization Services and Platforms: Weaknesses
Figure 26.4 Antibody Humanization Services and Platforms: Opportunities
Figure 26.5 Antibody Humanization Services and Platforms: Threats
Figure 27.1 Humira®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.2 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.3 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.4 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.5 Darzalex®: Annual Sales, 2016-2022 (CHF Million)
Figure 28.1 Future Opportunities Related to Upcoming Trends in Drug Discover

02-2729-4219

+886-2-2729-4219

License/价格

抗体发现市场（第五版）：服务和平台-按提供的服务类型、抗体发现方法、产生的抗体类型和关键区域分布：行业趋势和全球预测，2023-2035

Antibody Discovery Market (5th Edition): Focus on Services & Platforms-Distribution by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Key Geographies: Industry Trends & Global Forecasts, 2023-2035

目录

第 1 章前言

第 2 章研究方法

第 3 章经济与其他专案特定考量

第 4 章执行摘要

第 5 章简介

第 6 章抗体发现：製程与方法

第 7 章抗体发现服务提供者：市场状况

第 8 章企业竞争力分析

第 9 章公司简介：抗体发现服务提供者

第 10 章抗体发现技术：市场状况

第 11 章技术竞争力分析

第 12 章公司简介：抗体发现平台提供者

第 13 章伙伴关係与协作

第 14 章融资与投资分析

第 15 章市场影响分析：促进因素、限制因素、机会、挑战

第 16 章全球抗体发现服务市场

第 17 章抗体发现服务市场，依服务类型

第 18 章抗体发现服务市场，以抗体发现方法

第 19 章抗体发现服务市场，依生成抗体的类型划分

第 20 章抗体发现服务市场，依治疗领域划分

第 21 章抗体发现服务市场，依主要地区

第22章全球抗体发现技术市场

第 23 章抗体发现技术市场，依产生的抗体类型划分

第 24 章抗体发现技术市场，依主要地区

第 25 章授权协议的结构

第 26 章 SWOT 分析：抗体人源化服务提供者

第 27 章典型案例：最畅销抗体的药物发现过程

第 28 章抗体发现的未来成长机会

第 29 章结论

第 30 章管理见解

第 31 章附录 1：表格资料

第 32 章附录 2：公司与组织名单